Skip to content
Nonprofiteer
← GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

Form 990 for tax year 2022

Filed by GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC.

Totals

Total revenue
$56,212,963
Total expenses
$55,785,890
Contributions and grants received
$52,646,326
Grants paid
$263,496
Program service revenue
$0
Investment income
$2,631,898
Other revenue
$934,739
Total assets, end of year
$176,686,879
Total liabilities, end of year
$11,506,360
Net assets or fund balances, end of year
$165,180,519
Program services expenses (Part IX)
$49,671,462
Management and general expenses
$5,359,948
Fundraising expenses
$754,480
Program service expenses (Part III)
$49,671,462

Program services were 89.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $29,771,791

  • 1f · All other contributions, gifts and grants

    $22,874,535

  • 3 · Investment income

    total $2,653,344 · unrelated business $0 · excluded $2,653,344

  • 4 · Income from investment of tax-exempt bond proceeds

    total $0

  • 5 · Royalties

    total $33,423 · excluded $33,423

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 6d · Net rental income or loss

    total $0

  • 7a · Gross sales of assets other than inventory

    securities $496,224

  • 7b · Less cost or other basis and sales expenses

    securities $517,670

  • 7c · Gain or loss

    securities -$21,446

  • 7d · Net gain or loss

    total -$21,446 · excluded -$21,446

  • 8a · Fundraising events: gross income

    $0

  • 8b · Fundraising events: direct expenses

    $0

  • 8c · Net income from fundraising events

    total $0

  • 9a · Gaming: gross income

    $0

  • 9b · Gaming: direct expenses

    $0

  • 9c · Net income from gaming

    total $0

  • 10a · Gross sales of inventory

    $0

  • 10b · Cost of goods sold

    $0

  • 10c · Net income from sales of inventory

    total $0

  • 11a · Other revenue: MISCELLANEOUS INCOME

    total $901,316 · excluded $901,316

  • 11e · Other revenue, total

    $901,316

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $0 · program services $0

  • 2 · Grants to domestic individuals

    total $0

  • 3 · Grants to foreign organizations and individuals

    total $263,496 · program services $263,496

  • 4 · Benefits paid to or for members

    total $0

  • 5 · Compensation of officers, directors and key employees

    total $3,962,233 · program services $2,665,394 · management and general $1,140,409 · fundraising $156,430

  • 6 · Compensation of disqualified persons

    total $0

  • 7 · Other salaries and wages

    total $9,281,300 · program services $7,381,992 · management and general $1,551,113 · fundraising $348,195

  • 8 · Pension plan contributions

    total $872,684 · program services $697,269 · management and general $141,413 · fundraising $34,002

  • 9 · Other employee benefits

    total $1,472,446 · program services $1,158,078 · management and general $261,692 · fundraising $52,676

  • 10 · Payroll taxes

    total $671,088 · program services $512,410 · management and general $133,223 · fundraising $25,455

  • 11a · Fees: management

    total $0

  • 11b · Fees: legal

    total $794,814 · program services $739,134 · management and general $55,680

  • 11c · Fees: accounting

    total $153,496 · program services $30,000 · management and general $123,496

  • 11d · Fees: lobbying

    total $0

  • 11e · Fees: professional fundraising services

    total $0

  • 11f · Fees: investment management

    total $11,470 · management and general $11,470

  • 11g · Fees: other

    total $9,475,403 · program services $8,958,244 · management and general $505,159 · fundraising $12,000

  • 12 · Advertising and promotion

    total $0

  • 13 · Office expenses

    total $198,040 · program services $64,091 · management and general $132,306 · fundraising $1,643

  • 14 · Information technology

    total $1,182,625 · program services $599,562 · management and general $557,660 · fundraising $25,403

  • 15 · Royalties

    total $0

  • 16 · Occupancy

    total $1,126,468 · program services $841,629 · management and general $234,708 · fundraising $50,131

  • 17 · Travel

    total $596,907 · program services $421,117 · management and general $165,914 · fundraising $9,876

  • 18 · Travel or entertainment for public officials

    total $0

  • 19 · Conferences, conventions and meetings

    total $50,863 · program services $30,112 · management and general $20,134 · fundraising $617

  • 20 · Interest

    total $0

  • 21 · Payments to affiliates

    total $0

  • 22 · Depreciation, depletion and amortization

    total $404,474 · program services $300,060 · management and general $85,979 · fundraising $18,435

  • 23 · Insurance

    total $188,587 · program services $57,221 · management and general $131,366

  • 24a · Other expenses: R&D PROJECT EXPENSES

    total $24,854,874 · program services $24,854,874

  • 24b · Other expenses: DUES AND SUBSCRIPTIONS

    total $224,622 · program services $96,779 · management and general $108,226 · fundraising $19,617

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $0 · end of year $0

  • 2 · Savings and temporary cash investments

    beginning of year $181,065,855 · end of year $159,750,193

  • 3 · Pledges and grants receivable

    beginning of year $4,258,015 · end of year $4,239,015

  • 4 · Accounts receivable

    beginning of year $755,218 · end of year $1,094,599

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0 · end of year $0

  • 8 · Inventories for sale or use

    beginning of year $0 · end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $964,669 · end of year $1,057,756

  • 10a · Land, buildings and equipment: cost or other basis

    $5,492,163

  • 10b · Land, buildings and equipment: accumulated depreciation

    $4,767,787

  • 10c · Land, buildings and equipment, net

    beginning of year $457,341 · end of year $724,376

  • 11 · Investments: publicly traded securities

    beginning of year $0 · end of year $9,761,242

  • 12 · Investments: other securities

    beginning of year $0 · end of year $0

  • 13 · Investments: program-related

    beginning of year $0 · end of year $0

  • 14 · Intangible assets

    beginning of year $0 · end of year $0

  • 15 · Other assets

    beginning of year $59,698 · end of year $59,698

  • 17 · Accounts payable and accrued expenses

    beginning of year $9,644,841 · end of year $11,073,526

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $12,159,240 · end of year $419,100

  • 20 · Tax-exempt bond liabilities

    beginning of year $0 · end of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0 · end of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0 · end of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $116,142 · end of year $13,734

  • 27 · Net assets without donor restrictions

    beginning of year $165,640,573 · end of year $165,180,519

  • 28 · Net assets with donor restrictions

    beginning of year $0 · end of year $0

Mission and programs · 2022

Mission

TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.

Activities or mission (Part I)

TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.

  • RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. SIMPLICITB - SIMPLICITB IS EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF A NOVEL AND POTENTIALLY SHORTER DRUG REGIMEN (BPAMZ) FOR PATIENTS WITH DRUG-SENSITIVE (DS) AND DRUG-RESISTANT (MDR) PULMONARY TUBERCULOSIS (SPECIFICALLY MULTIDRUG-RESISTANT TB AND MONO-RESISTANCE TO ISONIAZID OR RIFAMPICIN). THE BPAMZ REGIMEN IS COMPRISED OF FOUR DIFFERENT ANTIMICROBIALS: BEDAQUILINE (B), PRETOMANID (PA), MOXIFLOXACIN (M) AND PYRAZINAMIDE (Z). THE DRUG REGIMEN IS ADMINISTERED FOR FOUR MONTHS TO PATIENTS WITH DS-TB, AND FOR SIX MONTHS TO PATIENTS WITH MDR-TB OR MONO-RESISTANCE TO RIFAMPICIN OR ISONIAZID. RESULTS IN THE DS-TB ARM WILL BE COMPARED TO A CONTROL GROUP OF THE STANDARD SIX-MONTH DRUG REGIMEN FOR DS-TB (HRZE). ZENIX - THE PHASE 3 ZENIX CLINICAL TRIAL EVALUATED THE BPAL REGIMEN TO TREAT EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS (XDR-TB) AND THOSE WITH PRE-XDR-TB AND MULTIDRUG-RESIDENT TB (MDR-TB) WHOSE PRIOR TREATMENT HAS FAILED OR WHO HAVE NOT TOLERATED THEIR TREATMENT. IT SOUGHT TO OPTIMIZE LINEZOLID DOSING AS PART OF THE BPAL REGIMEN, EVALUATING BOTH THE LINEZOLID DOSE AND THE LINEZOLID DURATION. THE TOP-LINE RESULTS OF ZENIX WERE PRESENTED AT IAS 2021, SHOWING THAT THE EFFECTIVENESS OF THE BPAL REGIMEN COULD BE MAINTAINED WITH REDUCED DOSING OF LINEZOLID. THESE RESULTS WERE ACCEPTED AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE IN THE SEPTEMBER 2022 ISSUE. THE RESULTS OF THE ZENIX TRIAL WERE INCORPORATED INTO A RAPID COMMUNICATION ON FORTHCOMING WORLD HEALTH ORGANIZATION GUIDELINES FOR THE TREATMENT OF DRUG-RESISTANT TB, ISSUED IN MAY 2022. THESE GUIDELINES WILL ENABLE A SIGNIFICANTLY BROADER PATIENT POPULATION TO BE TREATED WITH BPAL-BASED REGIMENS. BUILDING ON EVIDENCE FIRST DEVELOPED FROM TB ALLIANCE FROM THE NIX-TB AND ZENIX CLINICAL TRIALS, AS WELL AS THE TB-PRACTECAL TRIAL RUN BY MSF, ALMOST ALL PATIENTS WITH DR-TB CAN NOW BE TREATED IN SIX MONTHS WITH AN ALL-ORAL REGIMEN. NEW WORLD HEALTH ORGANIZATION GUIDELINES ALLOW FOR PROGRAMMATIC IMPLEMENTATION OF TREATING ALMOST ALL FORMS OF DRUG-RESISTANT TUBERCULOSIS WITH EITHER BPALM (A COMBINATION OF BEDAQUILINE, PRETOMANID, LINEZOLID, AND MOXIFLOXACIN) OR BPAL (BEDAQUILINE, PRETOMANID, AND LINEZOLID). LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2022, 50 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 7,000 PEOPLE WITH DRUG-RESISTANT TB. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT ARE EXPECTED TO BEGIN IN 2023.

    Expenses $44,011,395

  • PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MANAGES CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR new anti-TB medicines. It develops landmark studies to support policy developments seeking to accelerate anti-TB drug research and mobilizes networks of researchers and investigators worldwide to focus on the development of these medicines. TB Alliance also engages directly with national TB programs and multilateral institutions to accelerate global adoption of TB Alliance's novel TB treatment regimens. It works in close collaboration with private sector partners and employs novel mechanisms like volume guarantees in keeping with the organization's "AAA mandate" that all new products are adopted, available, and affordable to all in need.

    Expenses $4,892,742 · Grants $263,496

  • BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.

    Expenses $767,325

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Dr Melvin Spigelman

    PRESIDENT/CEO

    Total calculated
    $1,009,857
    From this org
    $908,988
    From related orgs
    $0
    Other
    $100,869
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $614,073
    Bonus
    $294,915
    Other
    $0
    Deferred
    $61,000
    Nontaxable benefits
    $39,869
    Filer's total
    $1,009,857
  • Dr Nader Fotouhi

    CHIEF SCIENTIFIC OFFICER

    Total calculated
    $642,018
    From this org
    $533,749
    From related orgs
    $0
    Other
    $108,269
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $408,888
    Bonus
    $124,861
    Other
    $0
    Deferred
    $51,153
    Nontaxable benefits
    $57,116
    Filer's total
    $642,018
  • Dr Eugene Sun

    SR. VP, RESEARCH & DEV'T

    Total calculated
    $635,466
    From this org
    $549,342
    From related orgs
    $0
    Other
    $86,124
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $421,778
    Bonus
    $127,564
    Other
    $0
    Deferred
    $50,907
    Nontaxable benefits
    $35,217
    Filer's total
    $635,466
  • Colleen Pero

    SECRETARY/CAO

    Total calculated
    $512,574
    From this org
    $445,698
    From related orgs
    $0
    Other
    $66,876
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $344,302
    Bonus
    $101,396
    Other
    $0
    Deferred
    $43,987
    Nontaxable benefits
    $22,889
    Filer's total
    $512,574
  • Robert Lorette

    SR. VP, BUSINESS DEVELOPMENT

    Total calculated
    $507,749
    From this org
    $426,569
    From related orgs
    $0
    Other
    $81,180
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $329,048
    Bonus
    $97,521
    Other
    $0
    Deferred
    $41,869
    Nontaxable benefits
    $39,311
    Filer's total
    $507,749
  • Angela Vanderploeg

    TREASURER/CFO

    Total calculated
    $499,191
    From this org
    $402,531
    From related orgs
    $0
    Other
    $96,660
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $308,367
    Bonus
    $94,164
    Other
    $0
    Deferred
    $40,428
    Nontaxable benefits
    $56,232
    Filer's total
    $499,191
  • Kathleen Schostack

    SR. VP, PROG. & ALLIANCE MGMT

    Total calculated
    $496,510
    From this org
    $416,684
    From related orgs
    $0
    Other
    $79,826
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $318,246
    Bonus
    $98,438
    Other
    $0
    Deferred
    $40,500
    Nontaxable benefits
    $39,326
    Filer's total
    $496,510
  • Sandeep Juneja

    SR. VP, MARKET ACCESS

    Total calculated
    $493,384
    From this org
    $397,339
    From related orgs
    $0
    Other
    $96,045
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $304,384
    Bonus
    $92,955
    Other
    $0
    Deferred
    $39,908
    Nontaxable benefits
    $56,137
    Filer's total
    $493,384
  • Dr Paul Bruinenberg

    SR. MEDICAL OFFICER

    Total calculated
    $472,775
    From this org
    $393,693
    From related orgs
    $0
    Other
    $79,082
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $336,592
    Bonus
    $57,101
    Other
    $0
    Deferred
    $39,052
    Nontaxable benefits
    $40,030
    Filer's total
    $472,775
  • Salah Foraida

    SR. DIRECTOR, MEDICAL AFFAIRS

    Total calculated
    $457,472
    From this org
    $408,334
    From related orgs
    $0
    Other
    $49,138
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $344,959
    Bonus
    $63,375
    Other
    $0
    Deferred
    $40,500
    Nontaxable benefits
    $8,638
    Filer's total
    $457,472
  • Maria Beumont

    VP, CHIEF MEDICAL OFFICER

    Total calculated
    $453,825
    From this org
    $380,489
    From related orgs
    $0
    Other
    $73,336
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $380,489
    Bonus
    $0
    Other
    $0
    Deferred
    $37,732
    Nontaxable benefits
    $35,604
    Filer's total
    $453,825
  • Pietro Turilli

    SR.VP, EXT AFF(AS OF 06/01/22)

    Total calculated
    $209,302
    From this org
    $161,060
    From related orgs
    $0
    Other
    $48,242
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $161,060
    Bonus
    $0
    Other
    $0
    Deferred
    $16,042
    Nontaxable benefits
    $32,200
    Filer's total
    $209,302
  • Dr Bruce Carter

    CHAIRMAN

    Total calculated
    $0
    Hours/week
    3
  • Dr Mario Raviglione

    VICE CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Eric Goosby

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Jane Griffiths

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Rasha Hibri

    DIRECTOR (AS OF 09/01/22)

    Total calculated
    $0
    Hours/week
    3
  • Sundar Kodiyalam

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • David Norton

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Ariel Pablos-Mendez

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Sangita Reddy

    DIRECTOR (THRU 05/15/22)

    Total calculated
    $0
    Hours/week
    3
  • Kim Schwartz

    DIRECTOR (AS OF 09/01/22)

    Total calculated
    $0
    Hours/week
    3
  • Shalini Sharp

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Mitchell Warren

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 7:
VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. SEE SCHEDULE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15A AND 15B FOR FURTHER DETAILS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type
form_990
Tax year
2022
Filed
31 October 2023
IRS schema version
2022v5.0
Source object
202333059349302318

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.